Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Contieri Roberto, Martini Alberto, Furrer Marc, D'Andrea David, Claps Francesco, von Deimling Markus, Soria Francesco, Mari Andrea, Bianchi Lorenzo, Tonin Elena, Flippot Ronan, Teoh Jeremy Y C, Marcq Gauthier, Desprez Pierre-Emmanuel, Pichler Renate, Ślusarczyk Aleksander, Subiela José Daniel, Del Giudice Francesco, Santarelli Valerio, Porreca Angelo, Amodeo Antonio, Pavan Nicola, Simonato Alchiede, Scilipoti Pietro, Perdonà Sisto, Gontero Paolo, van Rhijn Bas Wg, Hurle Rodolfo, Moschini Marco, Pradere Benjamin, Mertens Laura S, European Association of Urology‐Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group
Аннотация
PATIENTS AND METHODS: We performed a retrospective analysis of an individual patient data registry comprising 3196 patients with clinical T stage (cT)2-T4 N0M0 bladder cancer who underwent RC at 16 European centres (1990-2024). All treatment decisions, including the use of neoadjuvant chemotherapy, adjuvant therapy, and the FU schedule, were made at the discretion of the treating physician in accordance with the patient's preference. A Classification and Regression Tree (CART) analysis, incorporating pathological T and N stages, lymphovascular invasion (LVI), and other features, was used to stratify patients into Low-Risk and High-Risk groups for recurrence. The primary endpoint was recurrence-free survival (RFS). We used a landmark analysis to evaluate the conditional risk of recurrence at 1, 2, 3, 4, and 5 years after RC.
RESULTS: At a median FU of 81.8 months, 891 patients recurred. CART analysis identified a High-Risk group (pathological T stage [pT]3-pT4, node-positive disease, or pT2 with LVI) with significantly worse 5-year RFS than the Low-Risk group (37.8% vs 76.2%; P < 0.001). This stratification was strongly prognostic for recurrence (hazard ratio [HR] 4.29; 95% confidence interval 3.63-5.00), cancer-specific survival (subdistribution HR 5.80), and overall survival (HR 3.04) (all P < 0.001). Landmark analysis confirmed that the elevated risk persisted up to 4 years; however, the conditional risk for event-free patients converged after 5 years (HR 1.37; P = 0.3).
CONCLUSIONS: This study establishes a simple, pathologically derived model (pT3-4/pN+/pT2 + LVI) that effectively stratifies post-RC patients, enabling a risk-adapted FU strategy. Prospective evaluation of this framework is required to confirm its clinical utility, safety, and cost-effectiveness.